An update from Proteomics International Laboratories Ltd. ( (AU:PIQ) ) is now available.
Proteomics International Laboratories Ltd announced that their PromarkerD test has been validated through publication in the journal Diagnostics, proving its superiority over conventional tests in identifying the risk of diabetes-related chronic kidney disease. This development is expected to enhance the company’s market position by potentially revolutionizing diabetic kidney disease risk assessment and management, offering significant implications for healthcare stakeholders.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a company operating in the biotechnology industry, focusing on the development of diagnostic tests. Their primary product, PromarkerD, is designed for assessing the risk of diabetic kidney disease, aiming to improve patient outcomes and reduce healthcare costs.
YTD Price Performance: -39.38%
Average Trading Volume: 166,827
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$63.54M
For an in-depth examination of PIQ stock, go to TipRanks’ Stock Analysis page.